BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
So we did look at the marker in our study, in the ambassador study, and we found that it didn't matter if you were PD-L1 positive or negative, both groups had a benefit. So I think that's important because you're not worried that you're treating somebody that's PD-L1 negative and they're not going to have a benefit.
0
💬
0
Comments
Log in to comment.
There are no comments yet.